Replies to post #151369 on Biotech Values

[genisi]

Sounds like the beta amyloid biomarker results showed a trend in favor of Solanezumab but

There were no changes noted in other AD biomarkers such as tau, phosphorylated tau, hippocampal
volume, whole brain volume, or amyloid accumulation measured by PET imaging.

http://www.ctad.fr/07-download/Congres2012/PressRelease/Sola-Release_29Oct2012.pdf